clinical trial · NCT06264414
Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia
EMS·phase3·not yet recruiting·n = 262
Prostatic Hyperplasia, BenignErectile DysfunctionDTT106Dutasteride-Tamsulosin
brief summary
The purpose of this study is to assess the safety and efficacy of the DTT106 in the treatment of erectile dysfunction associated with benign prostatic hyperplasia
started
Feb 1, 2025
primary completion
Jun 1, 2026
completion
Jul 1, 2027
last updated
Feb 20, 2024
detailed description
After being informed about all risks and benefits and giving written informed consent, the subjects will undergo a 7-day screening to determine eligibility. After that, at visit 0 (V0), the subjects will be randomized to either the DTT106 or dutasteride + tamsulosin (0,5 mg + 0,4 mg).
official title
Phase III, Multicenter, Randomized, Double-blind Clinical Trial to Assess the Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol